Type of information: Licensing agreement
Compound: LYS228, IID572, MAK181
Company: Boston Pharmaceuticals (USA - MA) Novartis (Switzerland)
Therapeutic area: Infectious diseases
Type agreement: licensing
- antibiotic. LYS228 is a potential best-in-class monobactam which has entered clinical development and which has demonstrated activity against CRE with resistance caused by serine beta-lactamases (SBLs) and/or metallo beta-lactamases (MBLs).
- IID572 is a novel beta-lactamase inhibitor that may be used in combination with LYS228 or other beta-lactam antibiotics to expand their use against difficult-to-treat infections caused by a broader spectrum of CRE.
- MAK181 is an oral, first-in-class LpxC inhibitor for Pseudomonas infections.
Disease: carbapenem-resistant enterobacteriaceae (CRE) infections, Pseudomonas infections
- • On October 3, 2018, Novartis announced that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug candidates that are part of the Novartis Infectious Diseases portfolio, which have the potential to address the need for new agents to treat antibiotic resistant Gram-negative infections.
- Under the terms of the agreement, Boston Pharmaceuticals acquired worldwide rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas infections.
- Novartis will receive an upfront payment and is entitled to royalties and milestone payments for successfully commercialized medicines. In addition, Novartis will receive an equity stake in two new companies formed together with Boston Pharmaceuticals to further develop and commercialize these programs. Financial terms of the agreement were not disclosed.
- Boston Pharmaceuticals was launched in 2015 as a new pharmaceutical company model, providing a bridge to value realization for early stage clinical development programs in 2015. By offering strategic partnership options to biotech and pharmaceutical companies, its goal is to enable differentiated, under-resourced therapeutics to be developed and made available to patients with unmet medical needs. The company is funded by Gurnet Point Capital and is actively investing $600 million of committed capital to build a diversified portfolio.